RPL10 and plasma cell myeloma: Particularly, R98S has been described as a mutation hotspot with >90% of RPL10 mutations at this residue, accounting for ~8% of pediatric T-ALL.204,205 The mutants including I33V, E66G, I70M and I70L in RPL10 have been reported in multiple myeloma with low frequency (2%) and cluster in a region that is distinct from the mutation hotspot identified in T-ALL.206 An increase in RPL10 expression has been observed in ovarian and pancreatic cancers and linked to enhanced cell proliferation, invasion, survival, and resistance to oxidative stress.207,208